Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bebe Stores, Jabil, Lightbridge, MannKind: U.S. Equity Movers

June 23 (Bloomberg) -- Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.

Adobe Systems Inc. (ADBE US) dropped the most in the Standard & Poor’s 500 Index, sliding 7.3 percent to $30.38. The biggest maker of graphic-design programs forecast third-quarter revenue will be $950 million to $1 billion. Analysts on average estimated $962 million in sales.

Apogee Enterprises Inc. (APOG US) fell 8 percent, the most since April 8, to $11.72. The maker of glass products reported a 13-cent loss from continuing operations in the first quarter. That’s more than two times wider than the average analyst estimate, according to a Bloomberg survey.

Bebe Stores Inc. (BEBE US) rose 4.7 percent, the most since Feb. 26, to $6.63. The clothing retailer was upgraded to “neutral” from “underperform” by Cowen & Co.

CarMax Inc. (KMX US) gained 9.3 percent, the most since Sept. 22, to $21.85. The biggest U.S. used-car dealer was picked to replace XTO Energy Inc. (XTO US) in the Standard & Poor’s 500 Index, S&P said on its website. Separately, the company posted first-quarter profit that topped analysts’ estimates.

Medifast Inc. (MED US) rose 5.6 percent to $28.53 while Cogent Inc. (COGT US) increased 4.3 percent to $9.49 after being added to the S&P SmallCap 600.

Edwards Lifesciences Corp. (EW US) fell 4.9 percent, the most since November 2008, to $52.15. The Irvine, California-based company was cut to “neutral” from “buy” at Goldman Sachs Group Inc.

Jabil Circuit Inc. (JBL US) rose the most in the S&P 500, climbing 11 percent to $15.03. The St. Petersburg, Florida-based electronics manufacturer reported third-quarter profit excluding some items of 40 cents a share, beating the average analyst estimate of 34 cents a share in a Bloomberg survey.

Lightbridge Corp. (LTBR US) surged 61 percent, the most since October 2004, to $9.49. The developer of nuclear fuels said its all-metal fuel assembly design could reduce costs and increase power output by as much as 30 percent, compared with standard oxide fuel.

MannKind Corp. (MNKD US) rose 5.1 percent to $5.95, the biggest gain since June 10. The company founded by billionaire inventor Alfred Mann was reinstated with a “buy” rating at Bank of America Corp.

Philip Morris International Inc. (PM US) advanced 3.3 percent, the most since May 10, to $46.49. The world’s largest publicly traded tobacco maker forecast 2010 earnings per share will rise as much as 17 percent as improving markets and price increases offset the declining euro.

Rite Aid Corp. (RAD US) gained 5.9 percent, the most since Feb. 18, to $1.07. The third-largest U.S. drugstore chain posted a first-quarter loss of 9 cents a share, beating the 14-cent loss analysts estimated on average in a Bloomberg survey.

Royal Gold Inc. (RGLD US) fell 5.2 percent, the most since Dec. 17 to $48.63. The precious metals royalty company priced its offering of 5.2 million shares at $48.50 a share.

SulphCo Inc. (SUF US) rose 29 percent to 35 cents for the biggest rally in Russell 2000 Index. The petroleum technology company said in a statement on Globe Newswire it will install a mobile Sonocracking unit for Enterprise Products Operating LLC in Mont Belvieu, Texas.

Wilmington Trust Corp. (WL US) slid 11 percent to $11.56 for the biggest retreat in the Russell 1000 Index. Delaware’s largest bank was downgraded to “neutral” from “buy” at SunTrust Robinson Humphrey.

ZymoGenetics Inc. (ZGEN US) increased 6.1 percent to $4.53, the first gain in three days. The Seattle-based developer of treatments for cancer and autoimmune diseases was raised to “buy” from “neutral” at UBS AG.

To contact the reporter on this story: Lu Wang in New York at

To contact the editor responsible for this story: Nick Baker at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.